Direct Answer
190 SEC filers are classified under the Standard Industrial Classification code that describes the large-cap pharmaceuticals industry, and their latest annual reports show $454.1 billion of combined revenue and a median operating margin of -339.4%. Investors should still evaluate its revenue model, industry-specific KPIs, valuation framework and the risks that can change the group's economics.
Industry Overview
Large-cap pharmaceutical companies develop and sell prescription medicines worldwide and spend heavily on research and acquisitions. Results follow blockbuster products, patent timelines and pricing policy. The first numbers to compare across companies here are sales growth by product, pipeline and late-stage readouts and operating margin.
Key Industry Metrics
- Sales growth by product: Revenue change for each major drug. It shows which blockbusters are rising or fading, and whether growth is broad or depends on a few.
- Pipeline and late-stage readouts: Candidates in phase 3 and their trial results. They determine whether new launches can offset expiring drugs.
- Operating margin: Share of revenue left after production, research and selling costs. It reflects product mix and spending, and can swing with acquisition charges.
- Research and development spend: Annual funds put into discovering and testing drugs, often shown as a percent of sales. High spend supports future launches, but returns are uncertain.
- Patent expiry exposure: Share of sales tied to drugs losing exclusivity in coming years. It shows how much revenue must be replaced by new products.
Primary Macro Drivers
- New product launches: Strong launches replace sales lost from older drugs and drive growth, so uptake of new products moves sales growth by product.
- Pricing and reimbursement policy: Government and insurer decisions on price and coverage set net price per patient, which moves operating margin.
- Acquisitions: Buying companies or products refills the pipeline and adds revenue, but also brings integration cost, debt and write-down risk.
- Patent expirations: As exclusivity ends, sales on affected drugs fall sharply, so the expiry calendar sets how much new revenue is needed to grow.
Major Risks
- Patent cliffs: When blockbuster drugs lose exclusivity, sales drop quickly; watch patent expiry exposure and the pipeline's ability to replace it.
- US drug pricing reform: Negotiation, rebates and policy proposals could lower net prices on major drugs; watch net price trends and legislation.
- Trial failures: A failed late-stage study removes expected sales and can cause impairments; watch readout dates and pipeline stage.
- Litigation: Lawsuits over safety, pricing or patents can lead to large settlements; watch legal proceedings and reserves.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Defensive |
| Capital Intensity | Medium |
| Regulatory Intensity | High |
| Industry Maturity | Mature |
| Geographic Importance | Global |
Large-Cap Pharmaceuticals Filers in the SEC Record
190 companies with annual reports in the dataset are classified by the SEC in the Standard Industrial Classification code 2834. Their latest fiscal years end between 2022 and 2026, and together they reported $454.1 billion of revenue. Median revenue growth over the prior year was 11.1%. Median operating margin was -339.4% and median net margin -202.0%. Median total liabilities were 40% of total assets, and 40 of 190 reported a profit in their latest year.
| Company | Revenue | Growth | Operating margin | Net margin | Year |
|---|---|---|---|---|---|
| Johnson & Johnson | $94.2 billion | 6.0% | n/a | 28.5% | FY 2025 |
| Eli Lilly & Co | $65.2 billion | 44.7% | n/a | 31.7% | FY 2025 |
| Pfizer Inc | $62.6 billion | -1.6% | n/a | 12.4% | FY 2025 |
| Abbvie Inc. | $61.2 billion | 8.6% | 24.6% | 6.9% | FY 2025 |
| Bristol Myers Squibb Co | $48.2 billion | -0.2% | n/a | 14.6% | FY 2025 |
| Abbott Laboratories | $44.3 billion | 5.7% | 18.2% | 14.7% | FY 2025 |
| Viatris Inc | $14.3 billion | -3.0% | -18.6% | -24.6% | FY 2025 |
| Vertex Pharmaceuticals Inc / Ma | $12.0 billion | 8.9% | 34.8% | 32.9% | FY 2025 |
The 8 largest of 190 by revenue. Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. A company's SIC code reflects its main business as the SEC records it, so it can differ from how an index provider or analyst classifies the company, and a diversified group appears under only one code.
Where to Go Next
The Large-Cap Pharmaceuticals guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Life Sciences Tools
- Large-Cap Biotechnology
- Life Sciences Tools & Services
- Laboratory Instruments
- Managed Care
- Infection Prevention Products
- Managed Health Care
- Immunology Biotechnology
Put it to work
Frequently Asked Questions
What are the main KPIs for the Large-Cap Pharmaceuticals industry?
Key performance indicators for the Large-Cap Pharmaceuticals industry include: Sales growth by product, Pipeline and late-stage readouts, Operating margin, Research and development spend, Patent expiry exposure. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the Large-Cap Pharmaceuticals industry?
The Large-Cap Pharmaceuticals industry is generally defensive, meaning demand tends to remain relatively stable regardless of the economic cycle. Companies in this space can provide portfolio stability during recessions, though growth may lag in strong expansions.
What are the biggest risks in the Large-Cap Pharmaceuticals industry?
The primary risks for Large-Cap Pharmaceuticals companies include: Patent cliffs, US drug pricing reform, Trial failures, Litigation. Investors should assess each company's exposure to these factors and its track record of navigating them.